Ziprasidone Treatment of Refractory Generalized Anxiety Disorder: A Placebo-Controlled, Double-Blind Study
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
This 8-week, randomized, double-blind, placebo-controlled, flexible-dose trial assessed the efficacy, safety, and tolerability of ziprasidone in adults with treatment-resistant generalized anxiety disorder (GAD). Seventy-three subjects with treatment-resistant GAD were recruited, and 62 were randomized to either ziprasidone or placebo treatment at a ratio of 2:1 using a flexible dosing strategy (20-80 mg daily). Randomization was stratified into 2 subtypes of patients, those in whom the study drug was used as augmentation and those who have stopped their ineffective medications before entering the present trial (nonaugmented group). The subjects' clinical status was monitored weekly throughout the course of the study and included the Hamilton Anxiety Scale (primary outcome measure), the Clinical Global Impression Improvement and Severity of Illness scales, the Hamilton Depression Scale, the Sheehan Disability Scale, the Hospital Anxiety and Depression Scale, and the Abnormal Involuntary Movements Scale. Sixty-two patients were randomized to ziprasidone (n = 41) or placebo (n = 21). The dropout rate was 24%, consisting of 2 placebo patients and 13 ziprasidone patients. There was no statistically significant difference in the Hamilton Anxiety Scale score reduction between the drug and placebo groups. However, statistical trends were observed for an augmentation-study medication interaction effect, with ziprasidone patients producing more improvement in the nonaugmented than in the augmented group. This study provides pilot data for an augmentation-study medication interaction effect with ziprasidone patients producing more improvement in the nonaugmented than in the augmented group. Based on the data obtained in this trial and the subsequent power analyses, a future double-blind placebo-controlled trial should include at least 150 treatment-resistant GAD nonaugmented patients randomized to ziprasidone and placebo in a 1:1 ratio.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883
KUROKI, T., NAGAO, N., & NAKAHARA, T. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00910-2 · Cited by 146 · cited 1×
“The second-generation antipsychotic agents are thought to cause less extrapyramidal adverse effects and TD and, in addition, have various serotonergic properties implicated in their anxiolytic effects.(15) In fact, several studies of second-generation antipsychotic agents in schizophrenia and bipolar disorder show red…”
BackgroundAripiprazole as Augmentation Treatment of Refractory Generalized Anxiety Disorder and Panic Disorder
Hoge, E. A., Worthington, J. J., Kaufman, R. E., Delong, H. R., Pollack, M. H., & Simon, N. M. (2008) · CNS Spectrums · doi:10.1017/s109285290001676x · Cited by 58
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Not recommended adjunctive therapies: Ziprasidone does not appear to be effective as adjunctive therapy (Level 2, negative) [611].”
BackgroundBaldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“…may be beneficial [I (PCT)] (Brawman-Mintzer et al., 2005; Pollack et al., 2006; Altamura et al., 2011), but the evidence for quetiapine augmentation is inconsistent [I (PCT)] (Khan et al., 2011; Simon et al., 2008), and uncertain for ziprasidone augmentation [I (PCT)] (Lohoff et al., 2010).”
BackgroundMaher, A. R., Maglione, M., Bagley, S., Suttorp, M., Hu, J.-H., Ewing, B., Wang, Z., Timmer, M., Sultzer, D., & Shekelle, P. G. (2011) · JAMA · doi:10.1001/jama.2011.1360 · Cited by 558
Summary of the Comparative Effectiveness Review on Off-Label Use of Atypical Antipsychotics
Maher, A. R., & Theodore, G. (2012) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2012.18.s5-b.1 · Cited by 160
Aligning the many definitions of treatment resistance in anxiety disorders: A systematic review
Bokma, W. A., Wetzer, G. A. A. M., Gehrels, J. B., Penninx, B. W. J. H., Batelaan, N. M., & Balkom, A. L. J. M. (2019) · Depression and Anxiety · doi:10.1002/da.22895 · Cited by 58
“…et al., 2016), eight RCTs (Brawman‐Mintzer, Knapp, & Nietert, 2005; Castle, Gray, Neehoff, & Glue, 2017; Gloster et al., 2015; Hirschmann et al., 2000; Lohoff et al., 2010; Pollack et al., 2006; Rickels et al., 2012; Simon et al., 2009), four retrospective cohorts (Bakish et al., 1995; Cowley, Ha,…”
Metadata
- Authors
- Lohoff, F. W., Etemad, B., Mandos, L. A., Gallop, R., & Rickels, K.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2010-04
- Volume
- 30
- Issue
- 2
- Pages
- 185-189
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2061909107
- Cited by
- 38
- References
- 3
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ziprasidone Treatment of Refractory Generalized Anxiety Disorder: A Placebo-Controlled, Double-Blind Study. https://app.cochat.ai/papers/10.1097/jcp.0b013e3181d21951
- The paper
- Lohoff, F. W., Etemad, B., Mandos, L. A., Gallop, R., & Rickels, K. (2010). Ziprasidone Treatment of Refractory Generalized Anxiety Disorder: A Placebo-Controlled, Double-Blind Study. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e3181d21951
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.